Onderzoeker
Veerle Surmont
- Trefwoorden:Longkanker
- Disciplines:Kankertherapie
Affiliaties
- Vakgroep Inwendige ziekten en Pediatrie (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Inwendige ziekten (Departement)
Lid
Vanaf4 mrt 2013 → 30 sep 2018
Publicaties
1 - 10 van 51
- Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial(2023)
Auteurs: Mathieu Spaas, Nora Sundahl, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Fréderic Duprez, Yolande Lievens, Veerle Surmont, Lieve Brochez, Dries Reynders, et al.
Pagina's: 1205 - 1213 - The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients : results of the REQUITE study(2022)
Auteurs: Lotte van der Weijst, David Azria, Patrick Berkovic, Pierre Boisselier, Erik Briers, Renée Bultijnck, Jenny Chang-Claude, Ananya Choudhury, Gilles Defraene, Sylvian Demontois, et al.
Pagina's: 127 - 137 - Application of an ultrasensitive NGS-based blood test for the diagnosis of early-stage lung cancer : sensitivity, a hurdle still difficult to overcome(2022)
Auteurs: Malaïka Van der Linden, Bram Van Gaever, Lennart Raman, Karim Vermaelen, Ingel Demedts, Veerle Surmont, Ulrike Himpe, Yolande Lievens, Liesbeth Ferdinande, Franceska Dedeurwaerdere, et al.
- Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)(2022)
Auteurs: Lotte van der Weijst, Miguel E. Aguado-Barrera, David Azria, Patrick Berkovic, Pierre Boisselier, Erik Briers, Renée Bultijnck, Patricia Calvo-Crespo, Jenny Chang-Claude, Ananya Choudhury, et al.
Pagina's: 228 - 241 - Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials(2021)
Auteurs: Solange Peters, Sarah Danson, Dunson Ejedepang, Urania Dafni, Baktiar Hasan, Hoi-Shen Radcliffe, Frederique Bustin, Jacky Crequit, Linda Coate, Monica Guillot, et al.
Pagina's: 76 - 85 - Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma(2020)
Auteurs: Lennart Raman, Malaïka Van der Linden, Kim Van der Eecken, Karim Vermaelen, Ingel Demedts, Veerle Surmont, Ulrike Himpe, Franceska Dedeurwaerdere, Liesbeth Ferdinande, Yolande Lievens, et al.
- A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)(2020)Volume: 31
Auteurs: M. Reck, K. F. Mileham, D. A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, L. Paz-Ares, M. Sebastian, N Vinolas Segarra, et al.
Pagina's: S897 - S898 - Staging of nutrition disorders in non-small-cell lung cancer patients : utility of skeletal muscle mass assessment(2019)
Auteurs: Sami Antoun, Hugues Morel, Pierre-Jean Souquet, Veerle Surmont, David Planchard, Franck Bonnetain, Pascal Foucher, Thomas Egenod, Ivan Krakowski, Helene Gaudin, et al.
Pagina's: 782 - 793 - Coping strategy influences quality of life in patients with advanced lung cancer(2019)Volume: 54
Auteurs: Annelies Janssens, Sofie Derijcke, Danny Galdermans, Veerle Surmont, Els De Droogh, Anneke Lefebure, Erika Saenen, Elke Vandenbroucke, Ann-Marie Morel, Anna Sadowska, et al.
Aantal pagina's: 1 - Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC(2019)
Auteurs: Fabrice Barlesi, Edward B. Garon, Dong-Wan Kim, Enriqueta Felip, Ji-Youn Han, Joo-Hang Kim, Myung-Ju Ahn, Mary Jo Fidler, Matthew A. Gubens, Jr. de Castro, Gilberto, et al.
Pagina's: 793 - 801